Toxicology – Methemoglobinemia

Definition

Methemoglobinemia occurs when an excessive amount of hemoglobin is oxidized into methemoglobin, a form that cannot effectively carry and release oxygen to tissues. This produces functional tissue hypoxia despite adequate oxygen being present in the lungs.

Common Causes

Oxidizing drugs and chemicals associated with methemoglobinemia include:

• Benzocaine and prilocaine
• Phenazopyridine
• Dapsone
• Nitrates and nitrites
• Nitroglycerin
• Nitroprusside
• Nitric oxide
• Aniline compounds
• Sulfonamides
• Naphthalene
• Certain other industrial or pharmaceutical oxidizing agents

Mechanism of Action

Oxidizing substances convert the iron in hemoglobin from the normal ferrous state (Fe²⁺) to the ferric state (Fe³⁺).

Ferric hemoglobin cannot bind oxygen normally. In addition, the remaining normal hemoglobin holds onto oxygen more tightly, further reducing oxygen delivery to tissues.

Clinical Features

Early manifestations may include:

• Cyanosis
• Headache
• Dizziness
• Fatigue
• Nausea
• Mild shortness of breath

More severe poisoning can cause:

• Increasing dyspnea
• Confusion
• Altered mental status
• Tachycardia
• Seizures
• Coma
• Cardiovascular collapse

Blood may have a characteristic dark or “chocolate-brown” appearance.

Diagnosis

A characteristic finding is a saturation gap, in which oxygen measurements do not fit the patient’s clinical appearance.

Standard pulse oximetry becomes unreliable and often trends toward readings around the mid-80% range despite supplemental oxygen.

The diagnosis is confirmed by co-oximetry, which directly measures the percentage of methemoglobin. A routine arterial blood gas may show a normal or relatively preserved PaO₂ because it measures dissolved oxygen rather than hemoglobin’s ability to carry it.

Management

Treatment includes:

• Immediately stopping the responsible oxidizing agent
• Supplemental oxygen
• Supportive care and cardiovascular monitoring

Mild, asymptomatic cases may improve spontaneously as normal red-cell reducing systems convert methemoglobin back to functional hemoglobin.

Methylene blue is the principal antidote for clinically significant methemoglobinemia because it accelerates reduction of methemoglobin back to normal hemoglobin.

Special Consideration – G6PD Deficiency

Methylene blue requires NADPH for its action. In patients with G6PD deficiency, it may be less effective and can provoke hemolysis, so treatment requires particular caution and specialist guidance.

Key Points

• Methemoglobinemia results from oxidation of hemoglobin iron from Fe²⁺ to Fe³⁺.
• Cyanosis that does not improve as expected with oxygen should raise suspicion.
• Co-oximetry, rather than a routine pulse oximeter or PaO₂ alone, confirms the diagnosis.
• Methylene blue is the standard antidote for significant symptomatic toxicity.
• G6PD deficiency is important because it can complicate methylene blue treatment.